Format

Send to

Choose Destination
Clin Infect Dis. 2017 Apr 1;64(7):852-859. doi: 10.1093/cid/ciw865.

Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.

Author information

1
Pneumococcal Research, Murdoch Childrens Research Institute, and.
2
Centre for International Child Health, Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.
3
Ministry of Health and Medical Services, Suva, Fiji.
4
Department of Obstetrics and Gynecology, University of Melbourne, Royal Women's Hospital and Murdoch Childrens Research Institute, and.
5
Department of Microbiology and Infectious Disease, Royal Women's Hospital Regional World Health Organization HPV Reference Laboratory, Parkville, Victoria, and.
6
University of Queensland Diamantina Institute, Brisbane,Australia.
7
London School of Hygiene and Tropical Medicine, United Kingdom; and.
8
Department of Child Health, Menzies School of Health Research, Darwin, Northern Territory, Australia.

Abstract

Background:

The duration of antibody response following reduced human papillomavirus (HPV) vaccine doses has not been determined. We compared the antibody responses in girls previously vaccinated with zero, 1, 2, or 3 doses of quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 years previously.

Methods:

A prospective cohort study was undertaken in 200 Fijian girls 15-19 years of age. Approximately equal numbers of girls from 2 main ethnic groups (Fijians of Indian descent [FID] and Indigenous Fijians [iTaukei]) in Fiji were recruited for each dosage groups. Blood was drawn before and 28 days following a single dose of bivalent HPV vaccine (2vHPV; Cervarix, GlaxoSmithKline). We measured neutralizing antibodies (NAb) against HPV-6, -11, -16, and -18 using the pseudovirion-based neutralization assay.

Results:

After 6 years (before a dose of 2vHPV was given), the geometric mean NAb titers for all 4 HPV types were not statistically different between 2-dose (2D) and 3-dose (3D) recipients: HPV-6 (3D: 2216 [95% confidence interval {CI},1695-2896]; 2D: 1476 [95% CI, 1019-2137]; P = .07), HPV-11 (3D: 4431 [95% CI, 3396-5783]; 2D: 2951 [95% CI, 1984-4390]; P = .09), HPV-16 (3D: 3373 [95% CI, 2511-4530]; 2D: 3275 [95% CI, 2452-4373]; P = .89); HPV-18 (3D: 628 [95% CI: 445-888]; 2D: 606 [95% CI, 462-862]; P = .89), and were higher in FID than iTaukei girls. Although 1-dose recipients had significantly lower NAb titers than 2-/3-dose recipients, their NAb titers were 5- to 30-fold higher than unvaccinated girls. Post-2vHPV NAb titers against HPV-16 and -18 were not statistically different between girls who received 1, 2, or 3 doses of 4vHPV previously.

Conclusions:

Two doses of 4vHPV provide similar NAb titers as 3 doses for 6 years, although the clinical significance is unknown. A single dose of 4vHPV elicits antibodies that persisted for at least 6 years, and induced immune memory, suggesting possible protection against HPV vaccine types after a single dose of 4vHPV.

KEYWORDS:

adolescents; human papillomavirus vaccine; immune memory; neutralizing antibodies; reduced doses

PMID:
28034886
DOI:
10.1093/cid/ciw865
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center